Literature DB >> 19876919

Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion.

Michelle K Y Siu1, Esther S Y Wong, Hoi Yan Chan, Daniel S H Kong, Nina W S Woo, Kar Fai Tam, Hextan Y S Ngan, Queeny K Y Chan, Dominic C W Chan, Kelvin Y K Chan, Annie N Y Cheung.   

Abstract

Ovarian cancer is a gynecological malignancy with high mortality. Therefore, the identification of novel prognostic and therapeutic targets is important. p21-activated kinases (Paks) are involved in cytoskeleton reorganization. This study investigated the clinical significance of total and phosphorylated (p) Pak1 and Pak2 as well as their functional roles in ovarian cancer. Expressions of Pak1, p-Pak1 Thr(212), Pak2 and p-Pak2 Ser(20) in ovarian normal and cancerous cell lines as well as in clinical samples of ovarian tumors were evaluated. The effects of Pak1 and Pak2 on ovarian cancer cell functions were determined. Pak1, p-Pak1 and p-Pak2 were overexpressed in ovarian cancer cell lines, and clinical samples of ovarian cancers were compared with benign ovarian lesions/inclusion cysts. Similar Pak2 expression levels were observed among normal and cancerous cell lines and clinical samples. After multiple testing correction, high Pak1 and nuclear p-Pak1 expression in ovarian cancers was significantly associated with histological type and tumor grade, respectively. Pak1 and p-Pak1 expression was associated with poor overall and disease-free survival. Pak1 was an independent prognostic factor. Knockdown of Pak1 and Pak2 in ovarian cancer cell lines reduced cell migration and invasion but did not affect cell proliferation and apoptosis. Knockdown of Pak1 also reduced p38 activation and downregulated vascular endothelial growth factor. Conversely, ectopic Pak1 overexpression enhanced ovarian cancer cell migration and invasion in a kinase-dependent manner, along with increased p38 activation. Our findings suggest that Pak1, p-Pak1 and p-Pak2 play important roles in ovarian carcinogenesis. Pak1 and p-Pak1 may be potential prognostic markers and therapeutic molecular targets in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19876919     DOI: 10.1002/ijc.25005

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  38 in total

1.  p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.

Authors:  Michelle K Y Siu; Hoi Yan Chan; Daniel S H Kong; Esther S Y Wong; Oscar G W Wong; Hextan Y S Ngan; Kar Fai Tam; Hongquan Zhang; Zhilun Li; Queeny K Y Chan; Sai Wah Tsao; Staffan Strömblad; Annie N Y Cheung
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-06       Impact factor: 11.205

Review 2.  Functional proteomics to dissect tyrosine kinase signalling pathways in cancer.

Authors:  Walter Kolch; Andrew Pitt
Journal:  Nat Rev Cancer       Date:  2010-08-19       Impact factor: 60.716

Review 3.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

4.  PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Ashley Pandolfi; Robert F Stanley; Yiting Yu; Boris Bartholdy; Gopichand Pendurti; Kira Gritsman; Jacqueline Boultwood; Jonathan Chernoff; Amit Verma; Ulrich Steidl
Journal:  Blood       Date:  2015-07-13       Impact factor: 22.113

5.  Pak2 regulates hematopoietic progenitor cell proliferation, survival, and differentiation.

Authors:  Yi Zeng; Hal E Broxmeyer; Karl Staser; Brahmananda Reddy Chitteti; Su-Jung Park; Seongmin Hahn; Scott Cooper; Zejin Sun; Li Jiang; XianLin Yang; Jin Yuan; Rachelle Kosoff; George Sandusky; Edward F Srour; Jonathan Chernoff; D Wade Clapp
Journal:  Stem Cells       Date:  2015-05       Impact factor: 6.277

6.  Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.

Authors:  Samantha K McCarty; Motoyasu Saji; Xiaoli Zhang; David Jarjoura; Alfredo Fusco; Vasyl V Vasko; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2010-10-29       Impact factor: 5.678

7.  The Role of Ect2 Nuclear RhoGEF Activity in Ovarian Cancer Cell Transformation.

Authors:  Lauren P Huff; Molly J Decristo; Dimitri Trembath; Pei Fen Kuan; Margaret Yim; Jinsong Liu; Danielle R Cook; C Ryan Miller; Channing J Der; Adrienne D Cox
Journal:  Genes Cancer       Date:  2013-11

8.  PAK2 promotes migration and proliferation of salivary gland adenoid cystic carcinoma.

Authors:  Wei-Wei Deng; Lei Wu; Lin-Lin Bu; Jian-Feng Liu; Yi-Cun Li; Si-Rui Ma; Guang-Tao Yu; Liang Mao; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

9.  Promotion of liver and lung tumorigenesis in DEN-treated cytoglobin-deficient mice.

Authors:  Le Thi Thanh Thuy; Takashi Morita; Kayo Yoshida; Kenichi Wakasa; Masashi Iizuka; Tomohiro Ogawa; Mami Mori; Yumiko Sekiya; Shinobu Momen; Hiroyuki Motoyama; Kazuo Ikeda; Katsutoshi Yoshizato; Norifumi Kawada
Journal:  Am J Pathol       Date:  2011-06-02       Impact factor: 4.307

10.  Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity.

Authors:  P Song; B Song; J Liu; X Wang; X Nan; J Wang
Journal:  Clin Transl Oncol       Date:  2020-09-24       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.